# Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol

**Authors:** Trisha Peel, David McGiffin, Julian Smith, Andrew Forbes, Silvana Marasco, David Pilcher, Andrew J Stewardson, Dennis Petrie, Anton Y Peleg, Jessica Wisniewski, Samuel Forster, Paige Druce, Janine Roney, Sarah Astbury, Danielle Berkovic, Phoebe Mccracken, Paul S Myles, Trisha Peel

PMC · DOI: 10.1136/bmjopen-2025-115209 · BMJ Open · 2026-03-18

## TL;DR

This study compares different durations of antibiotic use after heart surgery to determine the shortest effective time to prevent infections.

## Contribution

The trial introduces an adaptive, multi-arm design to evaluate non-inferiority of shorter antimicrobial prophylaxis durations in cardiac surgery.

## Key findings

- The trial will assess if shorter antibiotic durations are non-inferior to longer ones in preventing surgical site infections.
- An adaptive design allows for early elimination of ineffective arms during interim analyses.
- The study will also evaluate the cost-effectiveness of different prophylaxis durations.

## Abstract

Administration of antibiotics before incising the skin (‘surgical antimicrobial prophylaxis’) is a critical infection prevention strategy in surgery. Extending doses of prophylaxis into the postoperative period is a common practice in cardiac surgery; however, the benefit has not been clearly established and may lead to emergence of antimicrobial resistance and patient harm. We present the protocol for a large international multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial to compare the incidence of surgical site infection after three different durations of postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery.

This adaptive, multi-arm multistage non-inferiority trial will compare intraoperative only (Arm A), to intraoperative and 24 hours (Arm B) and, to intraoperative and 48 hours (Arm C) of intravenous cefazolin and placebo as surgical antimicrobial prophylaxis in 9180 patients undergoing cardiac surgery. The adaptive design allows for potential dropping of any of the three arms if clear inferiority is indicated at any of the scheduled interim analyses. The trial will evaluate the clinical and cost-effectiveness of the three different antibiotic prophylaxis durations.

Ethics approval will be obtained at all participating sites. Results of the study will be submitted for publication in peer-reviewed journals and the key findings presented at national and international conferences. Patients and members of the public will also be involved in the dissemination and translation of the trial results.

NCT05447559.

## Linked entities

- **Chemicals:** cefazolin (PubChem CID 33255)

## Full-text entities

- **Diseases:** inflammatory (MESH:D007249), hypersensitivity (MESH:D004342), endocarditis (MESH:D004696), HCAIs (MESH:D003428), hypothermia (MESH:D007035), Unmet Need Neurological Disorders (MESH:D009461), Infectious Diseases (MESH:D003141), Rare Cancers (MESH:D009369), urinary tract infection (MESH:D014552), AKI (MESH:D058186), bacteraemia (MESH:C531821), diabetes (MESH:D003920), adverse drug reaction (MESH:D064420), bacterial infection (MESH:D001424), pneumonia (MESH:D011014), death (MESH:D003643), C. difficile (MESH:D003015), blood stream infection (MESH:D000086982), infection (MESH:D007239), Rare Disease (MESH:D035583), Postoperative (MESH:D019106), Postoperative infections (MESH:D013530)
- **Chemicals:** sodium chloride (MESH:D012965), urea (MESH:D014508), Cefazolin (MESH:D002437), vancomycin (MESH:D014640), creatinine (MESH:D003404), beta-lactam (MESH:D047090), NCT05447559 (-)
- **Species:** Clostridioides difficile (species) [taxon 1496], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13007059/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13007059/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC13007059/full.md

---
Source: https://tomesphere.com/paper/PMC13007059